EAU 2024 - The 39th Annual European Association of Urology Congress 2024
Apr 05 - Apr 08, 2024 | ParisFrance
LARVOL is not affiliated with The 39th Annual European Association of Urology Congress 2024 and all trademarks, logos, and brand names are property of their respective owners
Showing 22 abstracts linked to Trials
Extended follow-up from CheckMate 274 including the first report of overall survival outcomes
Clinical outcomes in patients with high-risk, post-cystectomy muscle-invasive bladder cancer (MIBC) with persistent circulating tumour DNA-negative (ctDNA-) status on serial testing: surveillance analysis from the IMvigor011 study
Phase 3 study of disitamab vedotin with pembrolizumab versus chemotherapy in patients with previously untreated locally advanced or metastatic urothelial carcinoma that expresses HER2 (DV-001; trial in progress)
SunRISe-3: TAR-200 plus cetrelimab or TAR-200 versus intravesical Bacillus Calmette–Guérin in patients with BCG-naive high-risk non–muscle-invasive bladder cancer
ARASAFE - A randomized, phase 3 trial comparing 3-weekly Docetaxel 75 mg/m2 (in a 3-week cycle) versus 2-weekly Docetaxel 50 mg/m2 (in a 4-week cycle) in combination with Darolutamide + ADT in patients with mHSPC.
WUTSUP-02-II-Neo-Dis-Tis: Investigating the efficacy and safety of neoadjuvant tislelizumab plus disitamab vedotin with adjuvant tislelizumab in upper urinary tract carcinoma—A phase II multi-center study.
PSMA-PET guided intensification of salvage radiotherapy after radical prostatectomy: A phase 2 randomized controlled trial
Efficacy and safety of the combination of Cisplatin plus Nab-paclitaxel and Nivolumab with radiotherapy after maximal tumor resection in non-metastatic muscle invasive Bladder Cancer (CNN-BC trial).
Phase 2 KEYNOTE-057 cohort C: Coformulations of pembrolizumab (pembro) and favezelimab or vibostolimab for patients with bacillus Calmette-Guérin (BCG)–unresponsive high-risk (HR) non–muscle-invasive bladder cancer (NMIBC)
A phase II clinical trial of neoadjuvant sasanlimab and stereotactic body radiation therapy as an in situ vaccine for cisplatin ineligible muscle invasive bladder cancer
ProstACT GLOBAL: A Phase 3 Study Best Standard of Care With and Without 177Lu-DOTA-rosopatamab (TLX591) for Patients with PSMA Expressing Metastatic Castration-resistant Prostate Cancer Progressing Despite Prior Treatment With a Novel Androgen Axis Drug
External validation of the Sexual Minorities and Prostate Cancer Scale (SMACS) in a sexual majority and minority population following robotic prostatectomy (RARP): NCT05772598
Screen E: Prostate cancer Enzalutamide (enza) with or without leuprolide in patients (pts) with European Association of Urology (EAU)-guideline-defined high-risk biochemically recurrent prostate cancer (BCR) following radical prostatectomy (RP) or radiation therapy (RT): EMBARK post hoc analysis
Screen D: Post-prostatectomy ED and rehabilitation Low-intensity extracorporeal shockwave therapy is safe immediately following robotic-assisted radical prostatectomy (NCT03862599)
Results from SunRISe-1 in patients with Bacillus Calmette–Guérin-unresponsive high-risk non–muscle-invasive bladder cancer receiving TAR-200 monotherapy